Tagged with CBER

BIO2023: FDA CBER’s Peter Marks on COVID-19 Regulatory Impact

USA BIO2023: FDA CBER’s Peter Marks on COVID-19 Regulatory Impact

USA During a panel discussion at the BIO International Convention, Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research (CBER) discussed the positive regulatory outcomes of the COVID-19 pandemic as well as the backlogs it created and the challenges of carrying the lessons learned forward. At…

Peter Marks – Director, Center for Biologics Evaluation and Research (CBER), US FDA

USA Peter Marks – Director, Center for Biologics Evaluation and Research (CBER), US FDA

USA Dr Peter Marks MD, PhD, director of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), highlights the Center’s contributions related to the regulatory science behind vaccine development, including vaccines to prevent COVID-19; the Center’s efforts to facilitate the advancement of the field…